Applied Therapeutics (APLT) late Wednesday said the US Food and Drug Administration has issued a complete response letter indicating its decision to not approve a new drug application for the company's govorestat drug candidate to treat galactosemia, citing "deficiencies in the clinical application."

Applied Therapeutics plunged almost 76% on Friday as volume swelled to more than 40.3 million shares compared to a daily average of about 3 million shares traded daily.

Aptevo Therapeutics (APVO) said on Friday it expects to execute a 1-for-37 reverse split of its common shares following the close of Tuesday's regular session in a bid to lift its stock price back above the Nasdaq minimum of $1 per share.

The biotechnology company's shares recently were down nearly 19%, staying just above its intraday low. More than 2.4 million shares had traded late in Friday's holiday-shortened session compared with an average of more than 6.9 million shares exchanged every day.

RumbleOn (RMBL) received a downgrade to neutral from buy by analysts at B. Riley Securities, who maintained its $7 price target. The analysts noted that they expect most potential buyers to remain on the sidelines until there is a more significant drop in interest rates and the outlook for the US economy improves further

RumbleOn shares were down 3.1%, partially recovering from a nearly 7% decline soon after Friday's opening bell. Trading volume was moderate, with more than 87,000 shares changing hands compared with a daily average of nearly 106,000 shares per day.

Price: 2.08, Change: -6.49, Percent Change: -75.73